Cancer channel
The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.
As Mystic unveiling nears, AZ keeps cancer options open with Chi-Med
June 29, 2017First ever targeted agent in renal cell carcinoma could be strong addition to AZ oncology portfolio
Five tech companies advancing against cancer
June 28, 2017New cancer tech devices for oncology screening, diagnosis and mental wellbeing.
The home advantage in cancer care
June 27, 2017The optimal cancer care pathway for this complex disease outside the hospital.
Immuno-oncology drugs: key to the Cancer Moonshot?
June 21, 2017Assessing the global challenges inhibiting immuno-oncology market access.
Meeting the needs of cancer patients and healthcare providers
June 20, 2017Complex and evolving cancer treatment pathways require comprehensive and tailored support programmes.
Sandoz weighs into European rituximab biosimilar market
June 19, 2017
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
June 14, 2017Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.
Lilly’s sarcoma drug Lartruvo recommended via Cancer Drugs Fund
June 13, 2017Lilly’s drug will be re-appraised in 2020
Amgen’s myeloma treatment Kyprolis gains NICE approval
June 13, 2017
Lynparza first PARP drug to show promise in breast cancer
June 4, 2017Data sets AZ up to file Lynparza in new indication
Taking up the gauntlet
May 31, 2017A review of Cancer Research UK’s Grand Challenge awards programme for the latest cancer research projects.
AZ highlights data from next-gen oncology drugs at ASCO
May 26, 2017Tesara and Takeda among other companies to publish data.
Keytruda wins another first with approval based on biomarkers
May 24, 2017For the first time, FDA approves drug on the basis of biomarkers, rather than location.
